Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALCNASDAQ:EQNASDAQ:GDTCNASDAQ:HOTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$1.91-4.0%$2.38$1.83▼$6.27$25.75M1.244,163 shs13,720 shsEQEquillium$0.39-3.2%$0.76$0.37▼$2.43$13.90M1.87360,244 shs133,586 shsGDTCCytoMed Therapeutics$2.20-2.2%$2.63$1.20▼$4.05$24.07M-0.9475,553 shs108,059 shsHOTHHoth Therapeutics$1.00-2.9%$1.13$0.58▼$3.80$6.90M0.843.41 million shs347,283 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica0.00%-1.00%-10.36%-39.51%-52.16%EQEquillium0.00%-47.55%-46.93%-45.22%-82.45%GDTCCytoMed Therapeutics0.00%-14.21%-18.28%-26.59%+3.18%HOTHHoth Therapeutics0.00%-4.63%+12.47%+35.33%-32.24%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALCCalciMedica2.4919 of 5 stars3.53.00.00.03.51.70.0EQEquillium2.7458 of 5 stars3.24.00.00.02.32.50.6GDTCCytoMed Therapeutics2.4649 of 5 stars3.55.00.00.03.00.00.0HOTHHoth Therapeutics2.9191 of 5 stars3.63.00.00.03.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 3.00Buy$18.00842.41% UpsideEQEquillium 2.33Hold$3.00664.72% UpsideGDTCCytoMed Therapeutics 3.00Buy$5.00127.27% UpsideHOTHHoth Therapeutics 3.25Buy$4.00300.00% UpsideCurrent Analyst Ratings BreakdownLatest HOTH, EQ, GDTC, and CALC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/28/2025EQEquilliumLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025EQEquilliumLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.003/10/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/4/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/4/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.002/11/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.001/23/2025HOTHHoth TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.001/7/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A$1.42 per shareN/AEQEquillium$41.10M0.34N/AN/A$0.64 per share0.61GDTCCytoMed TherapeuticsN/AN/AN/AN/A$0.78 per shareN/AHOTHHoth TherapeuticsN/AN/AN/AN/A$2.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$34.36M-$1.19N/AN/AN/AN/A-164.24%-103.53%5/12/2025 (Estimated)EQEquillium-$13.34M-$0.23N/AN/AN/A-10.05%-20.68%-10.77%5/8/2025 (Estimated)GDTCCytoMed Therapeutics-$3.13MN/A0.00∞N/AN/AN/AN/A4/28/2025 (Estimated)HOTHHoth Therapeutics-$7.84M-$1.33N/AN/AN/AN/A-89.68%-82.61%5/12/2025 (Estimated)Latest HOTH, EQ, GDTC, and CALC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024CALCCalciMedica-$0.48-$0.34+$0.14-$0.34N/AN/A3/27/2025Q4 2024EQEquillium-$0.22-$0.16+$0.06-$0.16N/A$4.39 million3/27/2025Q4 2024HOTHHoth Therapeutics-$0.39-$0.32+$0.07-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AGDTCCytoMed TherapeuticsN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedicaN/A4.154.15EQEquilliumN/A3.043.04GDTCCytoMed Therapeutics0.0421.54N/AHOTHHoth TherapeuticsN/A10.1710.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/AEQEquillium27.05%GDTCCytoMed Therapeutics0.04%HOTHHoth Therapeutics7.08%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%EQEquillium30.30%GDTCCytoMed TherapeuticsN/AHOTHHoth Therapeutics10.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3013.48 million7.88 millionNo DataEQEquillium4035.43 million24.70 millionNot OptionableGDTCCytoMed TherapeuticsN/A10.94 millionN/ANot OptionableHOTHHoth Therapeutics46.90 million6.18 millionNot OptionableHOTH, EQ, GDTC, and CALC HeadlinesRecent News About These CompaniesHoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent CoverageMarch 31 at 4:45 PM | prnewswire.comHoth Therapeutics, Inc.: Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study InitiationMarch 26, 2025 | finanznachrichten.deHoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study InitiationMarch 26, 2025 | prnewswire.comHoth Therapeutics to Revise Financial Statements Due to Auditing ErrorsMarch 25, 2025 | marketwatch.comHoth Therapeutics announces ‘positive’ results from study of HT-KITMarch 20, 2025 | finance.yahoo.comHT-KIT yields significantly reduced tumor growth, KIT expression in preclinical GIST modelsMarch 20, 2025 | bioworld.comHoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumoursMarch 19, 2025 | pharmabiz.comHoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatmentMarch 18, 2025 | prnewswire.comHoth Therapeutics, Inc.: Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in NeedMarch 10, 2025 | finanznachrichten.deHoth Dips on Drug ApplicationMarch 10, 2025 | baystreet.caHoth Therapeutics to submit Expanded Access application for HT-001March 10, 2025 | markets.businessinsider.comHoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in NeedMarch 10, 2025 | prnewswire.comHoth Therapeutics’ GDNF shows efficacy in obesity prevention and reversalMarch 5, 2025 | markets.businessinsider.comHoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidateMarch 5, 2025 | markets.businessinsider.comHoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual MeetingMarch 5, 2025 | prnewswire.comHoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver DiseaseMarch 4, 2025 | prnewswire.comHoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer TherapeuticFebruary 10, 2025 | contractpharma.comHoth Therapeutics announces collaboration with OnTargetx R&DFebruary 10, 2025 | markets.businessinsider.comHoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer TherapeuticFebruary 10, 2025 | prnewswire.comHoth Therapeutics expands at-the-market offering by $5 millionFebruary 8, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesHow to Build the Ultimate Everything ETF PortfolioBy Jeffrey Neal Johnson | March 16, 2025View How to Build the Ultimate Everything ETF PortfolioCostco Price Plunge Equals Opportunity for InvestorsBy Thomas Hughes | March 11, 2025View Costco Price Plunge Equals Opportunity for Investors4 Undervalued Growth Stocks to Buy and Hold for the Long TermBy Sarah Horvath | March 21, 2025View 4 Undervalued Growth Stocks to Buy and Hold for the Long Term3 Stocks With High ROE and Market-Beating Growth PotentialBy Nathan Reiff | March 16, 2025View 3 Stocks With High ROE and Market-Beating Growth PotentialSmall-Caps, Big Buybacks: 3 Stocks With Large Buyback CapacityBy Leo Miller | March 25, 2025View Small-Caps, Big Buybacks: 3 Stocks With Large Buyback CapacityHOTH, EQ, GDTC, and CALC Company DescriptionsCalciMedica NASDAQ:CALC$1.91 -0.08 (-4.02%) Closing price 04:00 PM EasternExtended Trading$1.92 +0.01 (+0.26%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Equillium NASDAQ:EQ$0.39 -0.01 (-3.23%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.01 (+2.98%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.CytoMed Therapeutics NASDAQ:GDTC$2.20 -0.05 (-2.22%) Closing price 03:58 PM EasternExtended Trading$2.20 +0.00 (+0.23%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.Hoth Therapeutics NASDAQ:HOTH$1.00 -0.03 (-2.91%) Closing price 04:00 PM EasternExtended Trading$1.02 +0.02 (+2.00%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Casey’s General Stores Insider Buys Shares of This Must-Own Stock U.S. Steel and Nippon Merger: Should Investors Bet on It? MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Lululemon Pulls Back Into Classic Dip-Buying Opportunity Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
